Valvular heart disease

Health Disparities Take Centerstage During Fifth Annual Heart Valve Disease Awareness Day

Retrieved on: 
Tuesday, February 23, 2021
Valvular heart disease, Anatomy, Heart, Circulatory system, Mitral valve, Mitral insufficiency, Heart valve, National Heart Valve Disease Awareness Day, Mitral valve prolapse

WASHINGTON, Feb. 23, 2021 /PRNewswire/ --On February 22, the Association of Black Cardiologists (ABC) joined more than 90 national organizations and thousands of patient advocates in recognizing the fifth annual Heart Valve Disease Awareness Day ("Valve Disease Day").

Key Points: 
  • WASHINGTON, Feb. 23, 2021 /PRNewswire/ --On February 22, the Association of Black Cardiologists (ABC) joined more than 90 national organizations and thousands of patient advocates in recognizing the fifth annual Heart Valve Disease Awareness Day ("Valve Disease Day").
  • Valve Disease Day offers an opportunity for the ABCto highlight risk factors, diagnosis, treatment and access to treatment as well as the disproportionate impact heart valve disease (HVD) has on communities of color in this country.
  • Millions of Americans have heart valve disease and every year, an estimated 25,000 people in the U.S. die from the disease.
  • Blacks also tend to be diagnosed with mitral valve disease, a common type of HVD, 15 years younger on average than Whites .

Progress being made but more needed for heart valve disease patients in Canada

Retrieved on: 
Monday, February 22, 2021
Medical specialties, Clinical medicine, Medicine, Cardiac surgery, Aortic valve, Percutaneous aortic valve replacement, Aortic stenosis, Heart valve, Bicuspid aortic valve, Valvular heart disease, Aortic valve replacement, Hybrid cardiac surgery

HVV Canada is calling on all provincial governments to prioritize heart valve disease care to ensure timely access to treatment.

Key Points: 
  • HVV Canada is calling on all provincial governments to prioritize heart valve disease care to ensure timely access to treatment.
  • Health Canada recently expanded the eligibility of low-risk patients for a minimally invasive procedure called Transcatheter Aortic Valve Implantation (TAVI) to treat severe aortic stenosis and bicuspid aortic valve disease.
  • This is an essential consideration if we are to continue bettering access to appropriate treatments for heart valve disease patients.
  • Heart Valve Voice Canada is a non-profit patient advocacy organization that works to improve the health and quality of life of people living with heart valve disease.

Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities

Retrieved on: 
Monday, February 22, 2021
Edwards Lifesciences, Valvular heart disease, Cardiac surgery, California, States of the United States, Medicine, National Heart Valve Disease Awareness Day

WASHINGTON, Feb. 22, 2021 /PRNewswire/ -- Today, Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual Heart Valve Disease Awareness Day ("Valve Disease Day") and the importance of addressing the disproportionate impact heart valve disease (HVD) has on America's Black communities.

Key Points: 
  • WASHINGTON, Feb. 22, 2021 /PRNewswire/ -- Today, Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual Heart Valve Disease Awareness Day ("Valve Disease Day") and the importance of addressing the disproportionate impact heart valve disease (HVD) has on America's Black communities.
  • Many Valve Disease Day awareness efforts this year have focused on highlighting the disparities in HVD diagnosis and treatment that Black Americans face.
  • As many as 11 million Americans have heart valve disease, yet general awareness of the disease is low.
  • The 2021 Heart Valve Disease Awareness Day campaign was made possible with support from Edwards Lifesciences Foundation and Abbott.

Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities

Retrieved on: 
Tuesday, February 16, 2021
Medicine, Medical terminology, Medical specialties, Edwards Lifesciences, Cardiac surgery, Articles, Disease, Valvular heart disease, Cardiology, Artificial heart valve

Many Valve Disease Day awareness efforts this year are focused on highlighting the disparities in HVD diagnosis and treatment that Black Americans face.

Key Points: 
  • Many Valve Disease Day awareness efforts this year are focused on highlighting the disparities in HVD diagnosis and treatment that Black Americans face.
  • As many as 11 million Americans have heart valve disease, yet general awareness of the disease is low.
  • "As many as 11 million Americans have heart valve disease, yet general awareness of the disease is low.
  • The 2021 Heart Valve Disease Awareness Day campaign was made possible with support from Edwards Lifesciences Foundation and Abbott.

Insights on the Transcatheter Treatment: Procedures and Heart Valve Global Market to 2025 - Key Drivers and Restraints

Retrieved on: 
Friday, February 12, 2021
Medicine, Clinical medicine, Medical specialties, Cardiac surgery, Percutaneous aortic valve replacement, Valvular heart disease, Mitral valve replacement, Minimally invasive procedure, Cardiology, Edwards Lifesciences, Valve replacement

Europe is the second-largest market after the U.S., and there are many established and early-stage companies that are working to enter the European TAVR market by developing improved transcatheter heart valve devices.

Key Points: 
  • Europe is the second-largest market after the U.S., and there are many established and early-stage companies that are working to enter the European TAVR market by developing improved transcatheter heart valve devices.
  • With regard to the European transcatheter treatment device market, it is growing mainly due to improved healthcare infrastructure, increasing prevalence of heart disease, improving diagnosis rates, and growing demand for minimally invasive and catheter-based treatment options.
  • Additionally, the increased patient population and improving diagnosis rate are likely to increase the demand for TAVR/TAVI and TMVR procedures within the region.
  • Japan is an established market in Asia-Pacific, while China and India are emerging markets that are growing rapidly.

Worldwide Transcatheter Treatment Procedures and Heart Valve Industry to 2025 - Major Developments Influencing the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 11, 2021
Health, Medical devices, Cardiology, Clinical medicine, Medicine, Medical specialties, Cardiac surgery, Percutaneous aortic valve replacement, Valvular heart disease, Mitral valve replacement, Cardiology, John G. Webb, Edwards Lifesciences

The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.
  • Transcatheter treatment includes procedure types such as TAVR, TAVI, TMVR and TMVI.
  • Transcatheter procedure approaches include transfemoral, transapical and transaortic procedures.
  • This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for transcatheter treatment for heart valve diseases.

Worldwide Prosthetic Heart Valve Industry to 2025 - North America Found to be the Largest Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 27, 2021
Health, Surgery, Cardiology, Medical devices, Medical specialties, Anatomy, Medicine, Cardiac surgery, Cardiology, Prosthetics, Heart valve, Artificial heart valve, Valvular heart disease, Aortic valve

In addition, the rise in adoption rate for transcatheter heart valve implantation procedure and new device approvals are expected to lead the growth of transcatheter heart valve market.

Key Points: 
  • In addition, the rise in adoption rate for transcatheter heart valve implantation procedure and new device approvals are expected to lead the growth of transcatheter heart valve market.
  • North America is expected to dominate the prosthetic heart valve market, followed by Europe, Asia-Pacific, and the rest of the world.
  • North America contributes to the largest market share due to the rapid growth in the ageing population and the high prevalence of valvular heart diseases.
  • Furthermore, the favourable reimbursement scenario and rising product approvals for the heart valve are also contributing to the growth of the North American prosthetic heart valve market.

Transcatheter Heart Valve Replacement Market Revenue to Cross USD 19.5 Bn by 2026: Global Market Insights, Inc.

Retrieved on: 
Tuesday, January 19, 2021
Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve replacement, Percutaneous aortic valve replacement, Heart valve, Aortic valve, Mitral valve replacement, Mitral valve, Valvular heart disease, Valve replacement

SELBYVILLE, Del., Jan. 18, 2021 /PRNewswire/ --According to the latest report "Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Repair and Replacement, Transcatheter Pulmonary Valve Replacement), Surgical Approach (Transfemoral Approach, Transapical Approach), Application (Aortic Valvular Heart Disease, Mitral Valvular Heart Disease, Pulmonary Valvular Heart Disease), End-use (Hospitals, Cath Labs), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026", by Global Market Insights, Inc., the market valuation of transcatheter heart valve replacement will cross $19.5 billion by 2026.

Key Points: 
  • SELBYVILLE, Del., Jan. 18, 2021 /PRNewswire/ --According to the latest report "Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Repair and Replacement, Transcatheter Pulmonary Valve Replacement), Surgical Approach (Transfemoral Approach, Transapical Approach), Application (Aortic Valvular Heart Disease, Mitral Valvular Heart Disease, Pulmonary Valvular Heart Disease), End-use (Hospitals, Cath Labs), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026", by Global Market Insights, Inc., the market valuation of transcatheter heart valve replacement will cross $19.5 billion by 2026.
  • Rising interest of manufacturers in emerging countries such as the Middle East and Africa will drive the transcatheter heart valve replacement market expansion.
  • Transapical approach segment in the transcatheter heart valve replacement market exceeded USD 1.16 billion in 2019.
  • Transcatheter mitral valve replacement devices are undergoing feasibility trials that will further propel the number of patients undergoing transcatheter mitral valve replacement.

The Foundry Announces Successful First-In-Human Procedure In Study Of Innovative Transcatheter Mitral Valve Repair Technology

Retrieved on: 
Monday, January 11, 2021
Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Valvular heart disease, Mitral valve, Cardiology, Heart valve repair, Heart valve, Mitral insufficiency, Regurgitation, Mitral valve replacement

The investigational Half Moon mitral valve repair device, developed through a unique partnership between Medtronic (NYSE:MDT) and The Foundry, is designed to restore function in a diseased mitral valve in patients with severe symptomatic mitral regurgitation (MR), a disease where blood leaks backwards within the heart due to the mitral valve's inability to close properly.

Key Points: 
  • The investigational Half Moon mitral valve repair device, developed through a unique partnership between Medtronic (NYSE:MDT) and The Foundry, is designed to restore function in a diseased mitral valve in patients with severe symptomatic mitral regurgitation (MR), a disease where blood leaks backwards within the heart due to the mitral valve's inability to close properly.
  • "Minimally invasive transcatheter heart valve repair can offer relief from mitral valve regurgitation without the need for traditional open-heart surgery," said Howard Song, M.D., Ph.D., OHSU cardiothoracic surgery division chief, who co-led the procedure.
  • The Half Moon mitral valve repair device is unique from other mitral valve repair technologies in maintaining more natural physiologic functionality of the mitral valve.
  • It is deployed using a transfemoral (through the leg) delivery catheter, which is navigated through the vasculature to the diseased native mitral valve.

Medtronic Evolut™ TAVI Now Licensed for Both Bicuspid Aortic Valves at Intermediate or Greater Risk and for Low Risk of Surgical Mortality

Retrieved on: 
Monday, January 11, 2021
Medical specialties, Circulatory system, Clinical medicine, Cardiac surgery, Valvular heart disease, Aortic valve, Percutaneous aortic valve replacement, Aortic stenosis, Cardiology, Bicuspid aortic valve, Heart valve, Aortic valve replacement

Medtronic's TAVI platform is currently the only system licensed for both bicuspid aortic valves (intermediate or greater risk), as well as all surgical risk categories in Canada.

Key Points: 
  • Medtronic's TAVI platform is currently the only system licensed for both bicuspid aortic valves (intermediate or greater risk), as well as all surgical risk categories in Canada.
  • Evolut is now indicated in Canada for severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low).
  • The expanded indication also allows patients with bicuspid aortic valves at extreme, high and intermediate risk of surgical mortality to also receive the procedure.
  • DOI:10.1056/NEJMoa1816885
    Reardon, Michael J. Evolut Surgical Replacement and Transcatheter Aortic Valve Implantation in Low Risk Patients - Evolut Low Risk.